More News! 24 Aug 2018Shire gets US market approval for rare inflammatory disease drug The UK-US biotech giant’s drug Takhzyro has been approved by the FDA to prevent attacks of hereditary angioedema, a rare… August 24, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases? Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time.… February 28, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2018Microsoft Joins Shire to Diagnose Rare Diseases Much Faster Microsoft has partnered with Shire and EURORDIS to accelerate the diagnosis of rare disease, a process that often takes years… February 20, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 13 Feb 2018How is Biotech Innovating to Treat Hemophilia? Let’s Review Experts say hemophilia treatment is at a 'precipice of a therapeutic revolution.' From antibodies to gene therapy, here are some… February 13, 2018 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 12 Sep 2017Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA The FDA has fast tracked Shire's candidate for chronic lung disease in extremely premature infants from Phase 2 of clinical… September 12, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment… July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jun 2017German Biotech Raises €25M to Fuel Diagnostics of Rare Diseases Centogene has raised €25M in a Series A round to support the global expansion of its genome analysis platform, which is… June 13, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2017Shire sells its RNA platform to a US-based Biotech Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from… January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016Results from 45% of Clinical Trials are kept Secret A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported.… November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016Shire’s leading Pancreatic Cancer drug is Back with a Bang Pancreatic cancer is one of the nastiest kinds and most difficult to treat; the EMA has granted marketing authorization to… October 18, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jan 2016The Biotech World is Buzzing: J.P. Morgan’s 2016 Phenomenon Kicks off this Week! Imagine a conference where all the Biotech CEOs and investors of the World come together...all the major players in this… January 14, 2016 - 4 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2016Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute The Janssen Human Microbiome Institute, the French National Institute for Agricultural Research (INRA) and Johnson & Johnson Innovation AND Takeda… January 7, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2015Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015 The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year. This was… November 4, 2015 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2015Shire’s Adderall alternative granted EMA approval for EU Intuniv, Shire's new anti-stimulatory product for children with attention-deficit hyperactivity disorder (ADHD) between 6-17 years old, is set to hit shelves… September 21, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 10 Mar 2015Live from Bio-Europe 2015: The product development challenges in the gene therapy field Gene Therapy is really the hot topic right now in the field of Biotech especially with technologies such as CRISPR and… March 10, 2015 - 3 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email